Kantonsspital St.Gallen
login

Heart rate variability decreases after 3 months of sustained treatment with fingolimod in patients with multiple sclerosis: a prospective clinical trial

Jochen Vehoff, Stefan Hägele-Link, Andrea Humm, Stefanie Müller, Rafael Sauter, Barbara Tettenborn & Thomas Hundsberger

abstract

Background and aims:
To prospectively investigate short- and mid-term changes of heart rate variability (HRV) in patients with relapsing-remitting multiple sclerosis (RRMS), being started on fingolimod.

Methods:
Patients (n=33) with RRMS starting treatment with fingolimod underwent a time-domain-based analysis of HRV (breathing at rest, deep breath, and in response to the Valsalva maneuver) shortly before, 4.5 hours and 3 months after first intake. Blood pressure changes after the Valsalva maneuver were used as a marker of the sympathetic noradrenergic system. We used a non-invasive continuous beat-to-beat heart rate and blood pressure monitoring. Additionally, the Fatigue Severity Scale and the refined and abbreviated Composite Autonomic Symptom Score were applied.

Results:
Significant changes in HRV in RRMS patients, following treatment with fingolimod, were detected. After an initial increase in HRV, 4.5 hours after the first intake of fingolimod, a substantial decrease in HRV occurred after 3 months on continuous treatment.

Conclusion:
Treatment with fingolimod in RRMS patients significantly decreases HRV after 3 months. Our findings might have implications for the long-term cardiac safety of fingolimod treatment, especially in patients with cardiovascular risk factors. Treatment with more selective sphingosine 1-phosphate receptor agonists might be more favorable in this population. Long-term effects (> 3 months) of fingolimod on HRV in RRMS patients remain to be investigated.
   
keywords autonomic nervous system, fingolimod, heart rate variability, mutliple sclerosis
   
citation Vehoff J, Hägele-Link S, Humm A, Müller S, sauter r, Tettenborn B, & Hundsberger T (2017). Heart rate variability decreases after 3 months of sustained treatment with fingolimod in patients with multiple sclerosis: a prospective clinical trial. In Session PRS2102 Autonomic nervous system 2 (pp. 2013): EAN.
   
type conference paper/poster (English)
name of conference 3rd EAN Congress (Amsterdam)
date of conference 25-6-2017
title of proceedings Session PRS2102 Autonomic nervous system 2
pages 2013
publisher EAN
contact Jochen Vehoff